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BACKGROUND: Thalidomide and lenalidomide are FDA approved for the treatment of multiple myeloma and, along with
pomalidomide, are being investigated in various other cancers. Although these agents display immunomodulatory, anti-angiogenic and
anti-apoptotic effects, little is known about their primary mode of therapeutic action in patients with cancer.
METHODS: As part of a continuing research effort, we have investigated the effects of these agents on the metastatic capacity of murine
colorectal cancer cell lines both in vivo and in vitro. Allied to these, we have studied their effects on the molecular pathways associated
with metastasis.
RESULTS: Results indicate that thalidomide, lenalidomide and pomalidomide significantly inhibit the metastatic capability of colorectal
carcinoma cells. Anchorage-independent growth, used as a coarse indicator of transformation, was significantly reduced, as were
migratory capacity and invasive competence. In addition, an in vivo experimental metastasis model also showed that treatment with
the drugs resulted in a significantly lower number of metastatic pulmonary nodules relative to control mice. Allied to these cellular
and phenotypic changes were alterations in molecular markers of metastasis and in intracellular signalling competency.
CONCLUSIONS: These results provide evidence that in addition to their immunomodulatory effects, thalidomide, lenalidomide and
pomalidomide can impair the metastatic capacity of tumours, and that this mechanism may involve alterations to cell signalling
functionality.
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There is growing evidence supporting a role for thalidomide-
derived immunomodulatory drugs known as IMiDs in cancer
therapy (Galustian et al, 2004; Bartlett et al, 2005; Shalapour et al,
2006; Melchert et al, 2007; Verhelle et al, 2007). This proprietary
class of therapeutic analogues, as exemplified by lenalidomide
(Revlimid, Celgene, Summit, NJ, USA, CC-5013) was developed
on the basis of structural activity relationship studies focussing
on molecular alterations to the central ring framework of
the thalidomide molecule as an approach to enhancing the
immunomodulatory characteristics of the agents (Stirling, 2001;
Bartlett et al, 2004). Allied to this enhancement, IMiDs, such as
thalidomide, display potent anti-proliferative, apoptotic and anti-
angiogenic properties both in vivo and in a wide spectrum of
tumour cell lines (Dredge et al, 2002, 2005; Shalapour et al, 2006;
Verhelle et al, 2007). At present, lenalidomide is approved by the
US Food and Drug Administration for use in patients with
myelodysplastic syndromes (associated with no or 5q-deletions),
and in combination with dexamethasone in patients with multiple
myeloma who have received one previous therapy (Dimopoulos
et al, 2007; Weber et al, 2007). However, there is a growing list of
other cancers, including non-small-cell lung cancer, pancreatic,
thymic, rectal apocrine carcinomas and angiosarcoma, in which
objective responses have been observed in monotherapy or in
combination with other therapies (Sharma et al, 2006; Kalmadi
et al, 2007; Liu et al, 2009a).
Despite the clinical merit of lenalidomide, the precise mechan-
ism of its action remains unclear, as does the primary method of
action whereby clinical activity is achieved. The inhibition of
metastasis, a direct anti-tumour effect, and immunomodulation
have all been associated with drug action, but the importance of
each appears to be dependent on the cancer type – specifically the
immune status of the patient and the molecular signature of the
tumour. In fact, it is possible that this broad spectrum of action
actually defines its clinical activity and appeal. For example, an
important facet of thalidomide and indeed the IMiDs, is the ability
to inhibit metastasis and angiogenesis (D’Amato et al, 1994;
Kumar et al, 2004; Chanan-Khan and Cheson, 2008). This
inhibition has been attributed to a number of modes of actions,
and a definitive answer is unavailable.
Angiogenesis and metastasis are hallmarks of cancer and are
processes that support and propagate the disease (Folkman, 1971;
Hanahan and Weinberg, 2000). They correlate with and predict
tumour stage for a number of neoplasms (Weidner et al, 1991, 1993;
Jaeger et al, 1995; Yuan et al, 1995), and as a consequence,
therapeutic approaches that inhibit them have been used success-
fully. There are currently limited in vitro data exploring the anti-
metastatic role of lenalidomide and pomalidomide in solid tumours,
and those available have used combinations with other anti-
angiogenic agents (Mangiameli et al,2 0 0 7 ;B l a n s f i e l det al, 2008).
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sTherefore, the primary aim of this study was to investigate the
effects of IMiDs on the metastatic capability of tumours through
both in vitro and in vivo approaches. Allied to this would be to study
the effects the drugs would have on intracellular signalling pathways
and how they correlated with the effects on biomarkers of
metastasis.
MATERIALS AND METHODS
Animals
Female BALB/c and C57BL/6 mice were purchased from and
maintained by the Biological Research Facility in a pathogen-free
environment at St George’s (University of London, London, UK).
Animals were acclimatised for at least 7 days before each
experiment and were used at the age of 9–13 weeks. All procedures
were conducted in accordance with and approved by the Home
Office of the United Kingdom.
Cell culture
The murine colorectal carcinoma (CRC) cell lines CT26 (syngeneic
to BALB/c) and CMT93 (syngeneic to C57BL/6) were obtained
from the Cancer Research UK Cell Production Laboratories
(London, UK) and maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma Ltd, Poole, UK) supplemented with 10%
(v/v) fetal bovine serum (FBS), 2mML -glutamine and 1 
penicillin/streptomycin (basal growth medium). All the cell lines
were incubated in a humidified atmosphere with 5% CO2 in air at
371C, and only cells with a passage number of o10 were used in
the experiments.
Reagents
Thalidomide, lenalidomide and pomalidomide were obtained from
Celgene Corp. (Summit, NJ, USA), and dissolved in DMSO to
create 10mM stock solutions that were maintained at  201C for no
longer than 1 week. For in vivo studies, the drugs were dissolved in
0.5% DMSO in PBS and stored at 41C for the duration of the
experiment.
Proliferation assays
To study the effects of thalidomide, lenalidomide and pomalido-
mide on cell growth, CT26 cells growing exponentially were added
to 96-well plates at a density of 5 10
4 per well. Drugs (1–1000mM)
were then added to the wells, ensuring an equal volume of 200ml
across the plates. Cell number/proliferation was measured at 72h
using a standard methylthiazoletetrazolium (MTT)-based assay
without modifications. Briefly, MTT (Sigma Ltd) was added to
each well to yield a working concentration of 0.4mgml
 1, and the
plates were returned to the incubator for a further 2h. After this
time, the medium was aspirated, 200ml of DMSO was then added
to each well and the plates were agitated gently for 5min before
measuring the optical density at 540nm in each well.
Flow cytometric analysis of the cell cycle
The distinct phases of the cell cycle were classified by DNA
staining using the fluorescent dye propidium iodide. These were
measured using flow cytometry according to methods described
previously (Liu et al, 2002). Data acquisition was performed within
1h using a Becton Dickinson FACSCalibur cytometer (BD
Biosciences, Oxford, UK), and gating was used to remove doublet
artefacts and to discriminate cells from debris. A total of 10000
cells were analysed, and the percentages of cells in G1, S and G2/M
phases were determined using the cell cycle analysis program,
CellQuest v3.4 (BD Biosciences).
Colony formation in soft agar
Anchorage-independent growth, a function of transformation, was
determined by assaying colony growth in soft agar. Colorectal
carcinoma cells were re-suspended in DMEM supplemented with
20% (v/v) FBS and containing 0.3% (w/v) Nobel agar (Sigma Ltd),
and a volume of 3ml was poured onto a 6-well plate containing a
pre-solidified agar base layer (0.5% (w/v) agar and 20% (v/v) FBS
in DMEM – 2ml). For drug treatments, cell suspensions were
supplemented with thalidomide, lenalidomide or pomalidomide at
1o r1 0mM. Plates were replenished every 5 days with 500ml basal
growth medium (with or without drugs), and colony formation
was assessed by light microscopy on day 21. The sizes of each
colony were assessed, and the viabilities of each colony were
confirmed by trypan blue dye exclusion.
Cell migration and invasion assays
Experiments assessing cell migration were performed using a
24-well chemotaxis chamber consisting of a transwell permeable
membrane with 3mm pore size. The chemoattractant in the
lower compartment of the chamber was basal growth medium
(600ml). Colorectal carcinoma cells (1 10
6 ml
 1) were re-sus-
pended in DMEM containing 2mML -glutamine and 0.1% bovine
serum albumin (BSA). For the treatment groups, cells were
co-cultured with each drug at a range of concentrations between
0a n d1 0 mM. Cells (300ml) were added to the upper com-
partment of the chemotaxis chamber, and they were allowed to
traverse through the membrane for 16h in a humidified atmos-
phere with 5% CO2 in air at 371C. Cells from either side of the
membrane were harvested mechanically and with trypsin, before
enumeration by cell counting with trypan blue dye to aid live–
dead cells discrimination. The percentage of cells traversing the
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Figure 1 Effect of IMiDs on cell growth parameters. CT26 cells were
cultured continuously with thalidomide, lenalidomide or pomalidomide (0–
30mM) for 3 days. Changes in cell numbers were assessed by the MTT
assay and are represented by values normalised to control samples with no
treatment (A). The effect on cell cycle distribution was also assessed (B).
Each data point represents the mean and s.d. (where appropriate) of at
least three separate experiments.
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spermeable membrane into the lower side of the chamber was then
calculated.
Cell-invasive capability was assessed using a similar chemotaxis
chamber set-up with few modifications. The ability of cells to
invade through the basement membrane was assessed by first
coating the upper surface of the polycarbonate membrane with
100mgml
 1 of growth factor-reduced Matrigel (BD Biosciences).
Matrigel was allowed to set at 371C for 30min, before adding cells
to the upper compartment of the chamber. Cells were allowed to
invade through the Matrigel and permeable membrane, before
being harvested using the same methods described above. Cell
recovery from the Matrigel layer was enhanced using the Cell
Recovery Solution (BD Biosciences), and the percentage of cells in
the lower compartment vs the upper chamber was calculated.
Immunoblotting analysis
Cells were harvested and total cellular protein was solubilised in
lysis buffer (New England Biolabs, Hitchin, UK) and resolved by
Tris-glycine electrophoresis using a 4–20% gradient gel according
to the method of Laemmli (1970) After transferring proteins to
nitrocellulose membranes (0.45mm), blocking was performed in
5% (w/v) non-fat milk in TTBS (0.1% (v/v) Tween-20 in TBS
(100mM Tris, 150mM NaCl, pH 7.6)). Primary antibody probing
was performed with anti-phosphoAKT
ser473, anti-AKT, anti-
phosphoMAPK
erk1/2, anti-MAPK, anti-VEGF-R1 (1:500 – Abcam
PLC, Cambridge, UK), anti-cadherin and anti-MMP-9. All primary
antibodies were obtained from New England Biolabs and used at a
dilution of 1:1000, unless stated otherwise. Anti-GAPDH was used
as a loading control (1:2000 – New England Biolabs). After three
washing steps in TTBS, horseradish peroxidase-conjugated anti-
species IgG1 was used as the secondary antibody (Amersham
Biosciences Ltd, Little Chalfont, UK). Bands were visualised using
the ECL-plus detection system (Amersham Biosciences Ltd).
Measurement of cytokine production
CT26 cells (1 10
5 cells) were cultured for 3 days in 6-well plates
in the basal medium supplemented with thalidomide, lenalidomide
or pomalidomide at concentrations between 0.01 and 30mM.
After incubation, the media were removed, debris removed by
micro-centrifugation at 13000g for 10min and stored at  801C
for further analysis. Changes in the expressions of a collection of
metastatic-related activating and inhibiting proteins were initially
screened and assessed using the TranSignal Mouse Angiogenesis
Antibody Array (Panomics Inc., Redwood City, CA, USA)
according to the manufacturer’s protocols. Furthermore, the levels
of VEGF (Peprotech EC Ltd, London, UK), IP10 and TIMP1 (both
from Bender MedSystems GmbH, Vienna, Austria) were assayed
using ELISA kits according to the manufacturer’s instructions.
In vivo murine experimental metastasis model
Exponentially growing CRC cells were harvested, washed and re-
suspended in PBS at a concentration of 1.3 10
5 per ml. Only cells
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Figure 2 Effect of IMiDs on anchorage-independent growth. CT26 and CMT93 cells were cultured on soft agar with thalidomide, lenalidomide or
pomalidomide (1 and 10mM), and colony formation assessed after 21 days. Non-viable–viable cells were discriminated using trypan blue exclusion (A), and
the presence of live colonies in each treatment group was enumerated (B). *Po0.05 when compared with thalidomide at the respective concentrations.
The representative photographs show a live and a dead colony before and after the addition of trypan blue dye. Each column represents the mean and s.d.
of three separate experiments. The average colony size was determined by measuring the area size using art software (C). Significant reductions in the
numbers of live colonies derived from CMT93 cells were observed after culture with 10mM of any of the three drugs (D).
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swith a viability of 490%, as established by trypan blue dye
exclusion analysis, were used. Mice (BALB/c for CT26 and C57BL/6
for CMT93) were anaesthetised with isoflurane and inoculated into
the tail vein with 150ml of cells. Thalidomide, lenalidomide or
pomalidomide (50mgkg
 1) was administered daily by intraper-
itoneal injection. Mice were killed 14 days after tumour cell
inoculation. For enumeration of pulmonary metastases of CRC
cells, the lungs were perfused intra-tracheally with a 15% solution
of Indian ink, resected and stabilised in Fekete’s solution (70%
(v/v) ethanol, 5% (v/v) formaldehyde and 750mM glacial acetic
acid in water). Metastases that appeared as white nodules on the
surface of the lungs were counted independently by two operators.
A parallel experiment was also performed with CT26 cells in
BALB/c mice using the slightly more active of the drugs. CT26 cells
(1 10
5 cell per ml) were pre-treated in vitro with 10mM
lenalidomide for 3 days, before inoculation into mice. Mice
(n¼10) were then treated with lenalidomide or vehicle (0.5% (v/v)
DMSO in PBS) for 14 days, before assessment of metastatic lesions
as described above.
Immunohistochemistry of the lungs from BALB/c mice
The lungs from BALB/c mice inoculated with CT26 cells and
treated with thalidomide, pomalidomide or lenalidomide were
fixed in an embedding compound and frozen in liquid nitrogen.
Cryosections (6mm) were fixed onto positively charged slides in
ice-cold acetone for routine haematoxylin and eosin staining
(Department of Pathology, St George’s Hospital, London, UK) and
for assessment of VEGF-R1 levels. Slides were blocked in 5% BSA
(w/v) in PBS before incubation at room temperature with anti-
VEGF-R1 (1:50; Abcam PLC) for 3h. After the three 5-min
washing steps in PBS, Alexa Fluor 568-conjugated secondary
antibody (1:50; Invitrogen Ltd, Paisley, UK) was applied to the
slides and incubated overnight at 41C in darkness. The slides were
washed three times in PBS and coverslips applied using mounting
media containing 40,6-diamidino-2-phenylindole (Vector Labora-
tories Inc., Burlingame, CA, USA). Sections were imaged using an
Olympus CKX-41 inverted microscope (Olympus, East Grinstead,
UK), and the VEGF-R1 expression was assessed independently by
two operators.
RESULTS
Thalidomide/IMiDs do not affect the proliferation of CT26
cells
The effect of IMiDs on cell proliferation was assayed by MTT
analysis, and the concentration ranges were clinically achievable
and tolerated. Results showed that thalidomide, lenalidomide and
pomalidomide at concentrations ranging between 1 and 10mM had
no significant effects on cell number and viability (Figure 1A).
Flow cytometric analysis indicated no changes in the sub-G1 phase
of the cell cycle that are suggestive of apoptosis, but highlighted a
possible arrest at the G1 phase of the cell cycle and concomitant
fall in the G2/M phase (Figure 1B).
Thalidomide/IMiDs reduce the clonogenic potential of
CRC cells
All the controls of CT26 and CMT93 cells that were treated with
DMSO showed significant growth in soft agar, with an average live
colony counts of 127±43 (mean±s.d.) and 114±8.1, respectively,
on day 21. In CT26 experiments, the percentage of live colonies as
assessed by trypan blue analysis was 96±3.5% (Figure 2A). The
numbers of live colonies was significantly reduced after culturing
with IMiDs (Po0.001) (Figure 2B). Equally, the average sizes of the
colonies in the treated cultures were reduced (Figure 2C).
Significant reductions in the numbers of live colonies were also
observed in CMT93 cells cultured with the drugs (Figure 2D).
Thalidomide/IMiDs reduce the FBS-mediated migration of
CRC cells
The effect of IMiDs on the metastatic capabilities of CT26 and
CMT93 cells was also examined by assessing the ability of cells to
migrate across a permeable membrane towards 10% FBS in a 16h
period. (Figure 3A and C). The IMiDs were used at concentrations
that were not cytotoxic at this short period of time, and the
Neg cont 0 0.01 0.1 1 10
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Figure 3 Effect of IMiDs on the migration and invasion of cells. CT26
(A, B) and CMT93 (C) cells were re-suspended in FBS-free growth
medium in the presence of absence of thalidomide, lenalidomide or
pomalidomide (0–10mM), and loaded into a chemotaxis chamber. The
percentage of migratory and invasive cells was established by counting the
cells in either compartment of a chemotaxis chamber after 16h. Each
column represents the mean and s.d. of at least three separate
experiments. The effect of only 10mM of each drug was assessed in
CMT93 (panel C).
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sviability of cells in both compartments of the chemotaxis chambers
was 490%. Migration in control wells, in which FBS was replaced
with 0.1% BSA was minimal (%migration o2.4±1.5%). There was
a concentration-dependent reduction in the migration of cells
when cultured with IMiDs, which reach significance at the higher
doses (Po0.001). In addition, there was no significant difference
in the migratory capacity between the drugs tested.
Thalidomide/IMiDs reduce the invasion of CRC cells
through Matrigel
The movement of CT26 and CMT93 cells through a layer of
extracellular matrix (Matrigel) was studied in the same chemotaxis
chambers used in the migration assays. The ability of cells to
invade through the layer and into 10% FBS was established by
counting the number of cells located on both sides of the
membrane. Cells were harvested from Matrigel using a proprietary
cell recovery solution that significantly reduced cell viability; hence
the percentage of invasive cells was calculated using total cell
numbers rather than viable cell numbers. Results showed that
IMiDs substantially reduced the percentage of invading cells
(Figure 3B and C).
Thalidomide/IMiDs alter the expression of metastatic
markers
To investigate whether the changes in the macroscopic metastatic
sub-systems were associated with changes in intracellular biomar-
kers of metastasis, whole cell lysates obtained from CT26 cells
cultured with IMiDs were analysed by immunoblotting. Results
showed that there was no significant effect to E-cadherin; however,
there were increases in the expressions of tumour VEGF-R1 and
MMP-9 (Figure 4A). Densitometry analyses of the autoradiograms
showed these changes to be statistically significant compared with
control samples treated with DMSO alone (Figure 4B).
Thalidomide/IMiDs reduce VEGF production by CT26 cells
In an attempt to establish the cytokines and growth factors in the
supernatant derived from CT26 cells, we used a proprietary
sandwich ELISA kit to assess the proteins present in the medium.
The signals for all the proteins on the ELISA array when assaying
the basal medium (DMEMþ10% FBS) were below the threshold
of detection. However, a number of proteins present in the
conditioned medium were flagged, of which, VEGF, IP10 and
TIMP1 were consistently seen (Figure 5A and B). We next assessed
the effects of the drugs on the capacity of CT26 cells to secrete
these cytokines using ELISA plates. Results showed that the drugs
did not affect the levels of IP10 and TIMP1; however, VEGF was
significantly reduced by treatment (Figure 5C). Furthermore, the
effect on VEGF was dose-dependent (Figure 4C).
Thalidomide/IMiDs alter levels of proteins associated with
intracellular signalling
To investigate whether intracellular signalling cascades were
affected by treatment with IMiDs, whole cell lysates from CT26
cells cultured with 10mM of thalidomide, lenalidomide or
pomalidomide for 3 days were analysed by immunoblotting.
Results showed significant reductions in pAKT and pERK
accompanied by an increase in VEGF-R1 levels (Figure 4D).
Thalidomide/IMiDs inhibit pulmonary metastasis in vivo
The propensity of CRC cells to spontaneously seed into and grow
within the lungs of mice after tumour cell injection into the tail
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Figure 4 Effect of the IMiDs on the expression of metastatic markers and intracellular signalling proteins. CT26 cells were cultured with thalidomide (tha),
lenalidomide (lena) or pomalidomide (poma) (0–30mM) for 3 days. The expressions of VEGF-R1, E-cadherin and MMP-9 were assessed by immunoblot
analyses. Representative blots are shown (A), and densitometric analysis using GAPDH as the loading control was carried out (B). The levels of VEGF within
the supernatant were also assessed by ELISA (C). The expressions of key signalling proteins after treatment (10mM – designated by a ‘T’) were assessed and
compared with controls with no treatment (‘C’) and those with equal DMSO solvent exposure (‘D’) (D). Each data point is the mean and s.d. of three
separate blots.
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svein was used as the in vivo model of metastasis. The method is
widely used, and easily defines metastatic potential – that is the
ability of tumour cells to seed, evade host immuno-surveillance
and to interact with the microenvironment by receiving growth
and survival signals from it (Khanna and Hunter, 2005). Results
showed that metastasis into the lung was significantly decreased in
BALB/c mice treated with IMiDs compared with that in untreated
mice (Po0.001 in all cases) (Figure 6A). As an example, the
average number of pulmonary nodules from 28 untreated BALB/c
mice was 95, whereas the average number in 15 mice treated
daily with 50mgkg
 1 of thalidomide was 17. These data were
recapitulated in C57BL/6 mice injected with the CMT93 cell line,
with significant reductions in the number of pulmonary nodules
after treatment with thalidomide, lenalidomide or pomalidomide
(Figure 6B).
In addition, immunohistochemistry analyses of the lungs
resected from BALB/c mice showed an absence of tumour-
infiltrating lymphocytes into the pulmonary cellular aggregates
(Figure 7). These analyses also recapitulated the increased
expression of VEGF-R1 after treatment with IMiDs compared
with samples derived from the untreated control group (Figure 7).
Pre-treatment with lenalidomide is sufficient to reduce
metastasis in vivo
CT26 cells were pre-cultured with lenalidomide for 3 days before
introduction into the mice as an attempt to understand the effect
of the drugs on metastatic capability. Pre-treatment did not result
in significant changes in cell number and viability. Results showed
that metastasis was reduced in the untreated mice inoculated with
CT26 cells pre-treated with lenalidomide (number of metastatic
nodules: 19±3.7 vs 43±4.6 in control mice inoculated with
untreated cells) (Figure 6C).
DISCUSSION
This study was undertaken as part of our larger remit to
understand the mechanism of action of the thalidomide-related
IMiDs in their inhibition of tumour progression. To this end, we
specifically investigated the effects of thalidomide, lenalidomide
and pomalidomide on the metastatic capability of a colon tumour
cell in a number of in vitro and in vivo models. Using in vitro
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smodels and the drugs at physiologically achievable and clinically
relevant concentrations (Galustian et al, 2009; Liu et al, 2009b), we
could assess the effects on metastasis that were independent of an
immune response. In addition, the colorectal CT26 cell line was
used exclusively as it was syngeneic to the BALB/c mouse, which
would allow in vivo and in vitro mechanistic studies to be related
to each other. In summary, we confirmed that these agents
significantly reduced metastasis capability directly, which was
independent of a specific cytotoxic effect. Moreover, we showed
that the inhibition was associated with, and mediated in part by,
alterations to intracellular signalling.
The clinical value of thalidomide against solid tumours may lie in
its immunomodulatory, anti-angiogenic and anti-metastatic proper-
ties. The immunomodulatory feature is believed to be a crucial
determinant of clinical success and as such, analogues of thalidomide
and those related to it have shown greatly increased potency for co-
stimulation of T-cell and NK cells (Corral et al, 1999; Haslett et al,
2003; Aragon-Ching et al, 2007; Wu et al,2 0 0 8 ) .T h e s ed r u g sh a v e
impressive activity in both haematological cancers (Galustian et al,
2004); however, it is not known whether the activity of solid tumours
will be as strong. In haematological cancers, direct anti-survival and
pro-apoptotic effects have been described for thalidomide/IMiDs
that are independent of an immune response, which may be the
underlying reason for therapeutic activity in neoplasia (Mitsiades
et al, 2002; Liu et al, 2004). It is important to understand that the
induction of tumour cytotoxicity can also be a result of an enhanced
immunological responses caused by IMiDs. The increased prolifera-
tion of a number of immune cell groups, including CD4-positive
and CD8-positive cells in addition to the initiation of dendritic
cell function, can lead to the activation of natural killer cells that
drive cytophagy and cytolysis (Davies et al, 2001; Hayashi et al,2 0 0 5 ;
Wu et al, 2008).
One in vitro characteristic of tumour cells, which distinguishes
them from normal non-tumourigenic cells, is their ability to grow
competently in soft agar (Freedman and Shin, 1974; Shin et al,
1975). This hallmark of phenotypic transformation is observed in
the majority of cancers, and occurs through the ability of the cell
to gradually escape their dependence on growth regulatory
mechanisms. Anchorage-independent growth has been correlated
with the in vivo development of murine tumour cells (Cifone
and Fidler, 1980) and with the propensity of tumour cells to
develop metastasis in vivo. Our results indicated that single-cell
suspension of untreated CT26 cells successfully developed into
relatively large colonies of viable cells, whereas those cultured with
IMiDs resulted in fewer and smaller-sized colonies, a large number
of which were composed of non-viable cells. It has been shown that
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sthe gradual loss of anchorage-independent growth capability
results in smaller colonies, indicating a loss of transformed
phenotype (Gu et al, 2006). Supplementary to this, the presence of
non-viable cells within these colonies suggests a cytotoxic effect
(Alley et al, 1982); however, the concentrations of IMiDs used in
the soft agar assay were not cytotoxic (Figure 1). Parenthetically,
these concentrations were used in all the in vitro studies as they
were clinically relevant and achievable in patients (Wu and
Scheffler, 2004). These data suggested that the ability to initiate
colony development independently of anchorage was not affected,
whereas the ability to maintain growth of these colonies was
compromised.
In support of the clonogenecity data, we next examined the
effect of IMiDs on tumour cell motility. There is a deficit of
information in this area, and although there are limited reports
detailing reduced migratory characteristics in endothelial cells,
there are very little data reporting these effects in tumour
cells (Dredge et al, 2005; Komorowski et al, 2006). In accordance
with the findings of the soft agar study, migration and invasion
capacity was significantly hampered by IMiD treatment. Further-
more, the reduction in motility was not a consequence of
increased cell death as the duration of exposure to drugs was
16h and the cell viabilities in either compartment of the
chemotaxis chambers were 490%. Taken together, IMiDs interfere
with three key stages of metastasis – namely transformation,
migration and invasion – and thus can reduce the overall
metastatic capability of tumour cells. Reassuringly, the frequency
of pulmonary tumours in a murine experimental metastasis model
was also reduced after treatment with IMiDs, which supported the
in vitro arm of our study. Furthermore, the reduction in
pulmonary metastatic nodules in mice inoculated with tumour
cells pre-treated with IMiDs, allied to the absence of lymphocyte
infiltration into pulmonary cell plaques, suggested that this anti-
metastatic effect of the drugs may have been independent of an
immune response.
Tumourigenicity is an iterative process that requires inter-
actions between tumour and the host microenvironment.
Paracrine communications between tumour cells and endothelial
cells exist to initiate, propagate and support tumour cells, and
involve cross-talk between a number of chemokines, such as
VEGF, IL-8 and IL-2 and their receptors (De Luca et al, 2008). In
particular, the VEGF-R family, including VEGF-R1 and VEGF-R2,
is known to be a crucial mediator of metastasis in vivo (Shibuya,
2001). These in turn, impact intracellular signalling cascades, such
as MAPK and PI3-K (Reddy et al, 2003; Chan, 2004). Indeed,
establishing the degree of metastasis and neovascularisation by
measuring biomarkers of endothelial cell function and their
interactions with tumour cells are prognostic indicators in
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Figure 7 Effect of thalidomide and pomalidomide on VEGF-R1 expression in pulmonary metastases. Immunohistochemistry was performed on lung
sections derived from mice treated with DMSO controls, thalidomide or pomalidomide. Metastases were identified as cellular aggregates (arrow) by H&E
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sneoplasia (Mustonen and Alitalo, 1995; Dales et al, 2004; Saad et al,
2004). Of the small group of markers studied, there was a
significant increase in VEGF-R1 in CT26 cells after treatment
with any of the IMiDs. This at first appeared to be counter-
predicted, as these proteins are normally associated with promot-
ing metastasis (Mustonen and Alitalo, 1995; Bergers et al, 2000).
However, VEGF-R1 has a unique mode of action in that it has a
relatively weak kinase activity even though it has a greater ligand
binding affinity (Mustonen and Alitalo, 1995), and hence it
functions primarily as a decoy receptor and ultimately sequesters
free VEGF. Ultimately, the incidence of VEGF binding the
functional subtype VEGF-R2 is reduced, which results in reduced
metastatic capacity (Beck and D’Amore, 1997; Yancopoulos et al,
2000). Furthermore, as MMP-9 is induced by VEGF-R1, any
increases in the latter would cause an increase in the former
(Hiratsuka et al, 2002), which would explain our observations.
Consequently, we explored the VEGF-R1 function further by
measuring free VEGF levels and the status of signalling cascades
downstream of this receptor kinase. These were reduced in all the
treatment groups in which an increase in the decoy VEGF-R1 was
observed. Parenthetically, as these drugs disrupt cytokine produc-
tion at an mRNA level, changes in their expressions and function
maybe due to post-translational processes (Liu et al, 2009b), which
may fortify their actions.
In summary, these data reaffirm the complexity of the data
surrounding the mechanism(s) of action(s) for the IMiDs, high-
lighting direct on-tumour effects in addition to the more classic
immunomodulatory effects of this class of drug. As part of our
continuing studies, we have clearly shown that the drugs
significantly reduce the clonogenic and metastatic capacity of
tumour cells in vitro. Allied to these findings, impressive reductions
in the frequency of pulmonary metastases were observed in mice
that appeared to be achieved independently of immune function. In
addition, we have also clearly shown a reduction in cell signalling in
tumour cells. Taken together, these drugs appear to reduce reverse
tumourigenicity and reduce metastasis. Finally, considering the
impact on VEGF-R signalling, it would be prudent to investigate the
benefit of combining these agents with inhibitors of receptor
tyrosine kinases; our models predicts possible enhanced effects.
This is an area that we are currently pursuing, and indeed,
highlights another useful facet to an already growing list of
mechanisms of actions for this class of IMiDs.
ACKNOWLEDGEMENTS
The authors would like to thank the staff at the Biological Research
Facility of St George’s, University of London, particularly Mr Will
Murphy, for technical assistance with the animal studies. The
authors also thank Ms Jamuna Jeevahan and Ms Anita Patel for
their help and advice with immunohistochemistry.
REFERENCES
Alley MC, Uhl CB, Lieber MM (1982) Improved detection of drug
cytotoxicity in the soft agar colony formation assay through use of a
metabolizable tetrazolium salt. Life Sci 31: 3071–3078
Aragon-Ching JB, Li H, Gardner ER, Figg WD (2007) Thalidomide
analogues as anticancer drugs. Recent Patents Anticancer Drug Discov
2: 167–174
Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of
thalidomide and its IMiD derivatives as anticancer agents. Nat Rev
Cancer 4: 314–322
Bartlett JB, Tozer A, Stirling D, Zeldis JB (2005) Recent clinical studies
of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93:
613–619
Beck Jr L, D’Amore PA (1997) Vascular development: cellular and
molecular regulation. FASEB J 11: 365–373
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K,
Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloprotei-
nase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol
2: 737–744
Blansfield JA, Caragacianu D, Alexander III HR, Tangrea MA, Morita SY,
Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008)
Combining agents that target the tumor microenvironment improves the
efficacy of anticancer therapy. Clin Cancer Res 14: 270–280
Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a
new approach to treating cancer. Br J Cancer 91: 1420–1424
Chanan-Khan AA, Cheson BD (2008) Lenalidomide for the treatment of
B-Cell malignancies. J Clin Oncol 26: 1544–1552
Cifone MA, Fidler IJ (1980) Correlation of patterns of anchorage-
independent growth with in vivo behavior of cells from a murine
fibrosarcoma. Proc Natl Acad Sci 77: 1039–1043
Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ,
Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine
modulation and T cell activation by two distinct classes of thalidomide
analogues that are potent inhibitors of TNF-alpha. J Immunol 163:
380–386
Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN,
Allasia C, Bonnier P, Taranger-Charpin C (2004) Prediction of
metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/
Tek and CD105 expression in breast cancer (n¼905). Br J Cancer 90:
1216–1221
D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an
inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082–4085
Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar
K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL,
Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide
and immunomodulatory derivatives augment natural killer cell cyto-
toxicity in multiple myeloma. Blood 98: 210–216
De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D,
Pinto A, Normanno N (2008) The role of the EGFR signaling in tumor
microenvironment. J Cell Physiol 214: 559–567
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL,
Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa ` R, Corso A,
Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple
Myeloma (010) Study Investigators (2007) Lenalidomide plus dexa-
methasone for relapsed or refractory multiple myeloma. N Engl J Med
357: 2123–2132
Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA,
Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally
administered lenalidomide (CC-5013) is anti-angiogenic in vivo and
inhibits endothelial cell migration and Akt phosphorylation in vitro.
Microvasc Res 69: 56–63
Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW,
Stirling D, Dalgleish AG (2002) Novel thalidomide analogues display
anti-angiogenic activity independently of immunomodulatory effects. Br
J Cancer 87: 1166–1172
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J
Med 285: 1182–1186
Freedman VH, Shin SI (1974) Cellular tumorigenicity in nude mice:
correlation with cell growth in semi-solid medium. Cell 3: 355–359
Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG (2004) Thalidomide-
derived immunomodulatory drugs as therapeutic agents. Expert Opin
Biol Ther 4: 1963–1970
Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk
S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG
(2009) The anti-cancer agents lenalidomide and pomalidomide inhibit
the proliferation and function of T regulatory cells. Cancer Immunol
Immunother 58: 1033–1045
Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod
DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS (2006) Phenotypic
characterization of telomerase-immortalized primary non-malignant and
malignant tumor-derived human prostate epithelial cell lines. Exp Cell
Res 312: 831–843
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70
Inhibiting metastasis with IMiDs
WM Liu et al
811
British Journal of Cancer (2009) 101(5), 803–812 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sHaslett PA, Hanekom WA, Muller G, Kaplan G (2003) Thalidomide and a
thalidomide analogue drug costimulate virus-specific CD8+ T cells in
vitro. J Infect Dis 187: 946–955
Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S,
Chauhan D, Treon SP, Richardson P, Anderson KC (2005) Molecular
mechanisms whereby immunomodulatory drugs activate natural killer
cells: clinical application. Br J Haematol 128: 192–203
Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley
JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular
endothelial growth factor receptor-1 is involved in lung-specific
metastasis. Cancer Cell 2: 289–300
Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman
FM, Carroll PR (1995) Tumor angiogenesis correlates with lymph node
metastases in invasive bladder cancer. J Urol 154: 69–71
Kalmadi S, Davis M, Dowlati A, O’Keefe S, Cline-Burkhardt M, Pelley RJ,
Borden E, Dreicer R, Bukowski R, Mekhail T (2007) Phase I trial of three-
weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in
patients with advanced solid tumors. Invest New Drugs 25: 211–216
Khanna C, Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26:
513–523
Komorowski J, Jerczyn ´ska H, Siejka A, Baran ´ska P, Ławnicka H, Pawłowska
Z, Stepien ´ H (2006) Effect of thalidomide affecting VEGF secretion, cell
migration, adhesion and capillary tube formation of human endothelial
EA.hy 926 cells. Life Sci 78: 2558–2563
Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust
JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV (2004) Effect of
thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
Leukemia 18: 624–627
Laemmli UK (1970) Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227: 680–685
Liu W, Nizar S, Dalgleish A (2009a) Gemcitabine and lenalidomide
combination in a patient with metastatic pancreatic cancer – a case
study. Med Oncol (e-pub ahead of print 12 May 2009; doi:10.1007/s12032-
009-9228-6)
Liu WM, Laux H, Henry J, Bolton T, Dalgleish A, Galustian C (2009b)
A microarray study of altered gene expression in colorectal cancer cells
after treatment with immunomodulatory drugs: differences in action
in vivo and in vitro. Mol Biol Rep (e-pub ahead of print 14 July 2009;
doi:10.1007/s11033-009-9614-3)
Liu WM, Lawrence AJ, Joel SP (2002) The importance of drug scheduling
and recovery phases in determining drug activity. Improving etoposide
efficacy in BCR-ABL-positive CML cells. Eur J Cancer 38: 842–850
Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, Joel SP,
Malpas JS (2004) s-Thalidomide has a greater effect on apoptosis than
angiogenesis in a multiple myeloma cell line. Hematol J 5: 247–254
Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller
GW, Stirling DI, Libutti SK (2007) Combination therapy targeting the
tumor microenvironment is effective in a model of human ocular
melanoma. J Transl Med 5: 38
Melchert M, Kale V, List A (2007) The role of lenalidomide in the treatment
of patients with chromosome 5q deletion and other myelodysplastic
syndromes. Curr Opin Hematol 14: 123–129
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG,
Hideshima T, Munshi NC, Treon SP, Anderson KC (2002) Apoptotic
signaling induced by immunomodulatory thalidomide analogs in human
multiple myeloma cells: therapeutic implications. Blood 99: 4525–4530
Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases
involved in angiogenesis. J Cell Biol 129: 895–898
Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor
progression and invasion. Cancer Metastasis Rev 22: 395–403
Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004)
Endoglin (CD105) and vascular endothelial growth factor as prognostic
markers in colorectal cancer. Mod Pathol 17: 197–203
Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C,
van Landeghem FK, Taube T, Fichtner I, Bu ¨hrer C, Henze G, Seeger K,
Wellmann S (2006) The thalidomide analogue, CC-4047, induces
apoptosis signaling and growth arrest in childhood acute lymphoblastic
leukemia cells in vitro and in vivo. Clin Cancer Res 12: 5526–5532
Sharma RA, Steward WP, Daines CA, Knight RD, O’Byrne KJ, Dalgleish AG
(2006) Toxicity profile of the immunomodulatory thalidomide analogue,
lenalidomide: phase I clinical trial of three dosing schedules in patients
with solid malignancies. Eur J Cancer 42: 2318–2325
Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system
involved in angiogenesis. Cell Struct Funct 26: 25–35
Shin SI, Freedman VH, Risser R, Pollack R (1975) Tumorigenicity of virus-
transformed cells in nude mice is correlated specifically with anchorage
independent growth in vitro. Proc Natl Acad Sci 72: 4435–4439
Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin
Oncol 28: 602–606
Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L,
Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-
Girona A, Muller GW, Brady HA, Chan KW (2007) Lenalidomide and
CC-4047 inhibit the proliferation of malignant B cells while expanding
normal CD34+ progenitor cells. Cancer Res 67: 746–755
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA,
Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin
J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study
Investigators (2007) Lenalidomide plus dexamethasone for relapsed
multiple myeloma in North America. N Engl J Med 357: 2133–2142
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor
angiogenesis correlates with metastasis in invasive prostate carcinoma.
Am J Pathol 143: 401–409
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis
and metastasis -correlation in invasive breast carcinoma. N Engl J Med
324: 1–8
Wu A, Scheffler MR (2004) Multiple-dose pharmacokinetics and safety of
CC-5013 in 15 multiple myeloma patients. J Clin Oncol 22: 2056
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett
JB (2008) Lenalidomide enhances natural killer cell and monocyte-
mediated antibody-dependent cellular cytotoxicity of rituximab-treated
CD20+ tumor cells. Clin Cancer Res 14: 4650–4657
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000)
Vascular-specific growth factors and blood vessel formation. Nature 407:
242–248
Yuan A, Yang PC, Yu CJ, Lee YC, Yao YT, Chen CL, Lee LN, Kuo SH, Luh
KT (1995) Tumor angiogenesis correlates with histologic type and
metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 152:
2157–2162
Inhibiting metastasis with IMiDs
WM Liu et al
812
British Journal of Cancer (2009) 101(5), 803–812 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s